Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been acquired by the US biotech company for $95.50 per share in cash to become the latter’s fully-owned subsidiary. Forty Seven will be delisted from the Nasdaq Global Select Market. The […]
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]
Descovy FDA approval : Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) has been approved by the US Food and Drug Administration for HIV Pre-Exposure Prophylaxis (PrEP) or in other words prevention of HIV infection.. PrEP is defined as an HIV prevention method in which medicine is taken everyday before […]
US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its subsidiary Kite, a California-based cell therapy company, which the former acquired for about $11.9 billion in 2017. Christi L. Shaw, who will also become a member of the senior leadership team of Gilead Sciences, is said to […]